| Primary |
| Pneumonia |
12.9% |
| Pyrexia |
12.4% |
| Upper Respiratory Tract Inflammation |
10.0% |
| Nasopharyngitis |
9.5% |
| Bronchitis |
7.1% |
| Epilepsy |
7.1% |
| Pharyngitis |
5.8% |
| Infection Prophylaxis |
4.1% |
| Cough |
3.7% |
| Hiv Infection |
3.7% |
| Respiratory Tract Infection |
3.7% |
| Periodontal Disease |
2.9% |
| Hypertension |
2.5% |
| Infection |
2.5% |
| Pneumonia Mycoplasmal |
2.5% |
| Reflux Oesophagitis |
2.5% |
| Gingival Abscess |
2.1% |
| Bacterial Infection |
1.7% |
| Disseminated Intravascular Coagulation |
1.7% |
| Insomnia |
1.7% |
|
| Rhabdomyolysis |
12.1% |
| Loss Of Consciousness |
8.8% |
| Vomiting |
7.7% |
| Pneumonia |
6.6% |
| Delirium |
5.5% |
| Haematuria |
5.5% |
| Pyrexia |
5.5% |
| Tremor |
5.5% |
| Chromaturia |
4.4% |
| Ocular Hyperaemia |
4.4% |
| Parosmia |
4.4% |
| Feeling Abnormal |
3.3% |
| International Normalised Ratio Increased |
3.3% |
| Interstitial Lung Disease |
3.3% |
| Intraocular Pressure Increased |
3.3% |
| Melaena |
3.3% |
| Palpitations |
3.3% |
| Rash |
3.3% |
| Stevens-johnson Syndrome |
3.3% |
| Stomatitis |
3.3% |
|
| Secondary |
| Hiv Infection |
29.4% |
| Nasopharyngitis |
11.9% |
| Haemorrhoids |
6.7% |
| Pneumonia |
5.8% |
| Acquired Immunodeficiency Syndrome |
5.2% |
| Factor Viii Deficiency |
4.3% |
| Lower Gastrointestinal Haemorrhage |
4.3% |
| Infection |
4.0% |
| Bronchitis |
3.4% |
| Product Used For Unknown Indication |
3.4% |
| Pyrexia |
3.4% |
| Upper Respiratory Tract Inflammation |
2.8% |
| Hypertension |
2.4% |
| Opportunistic Infection Prophylaxis |
2.4% |
| Infection Prophylaxis |
2.1% |
| Bacteraemia |
1.8% |
| Drug Use For Unknown Indication |
1.8% |
| Prophylaxis |
1.8% |
| Gastritis |
1.5% |
| Pharyngitis |
1.5% |
|
| Stevens-johnson Syndrome |
9.3% |
| White Blood Cell Count Decreased |
9.3% |
| Haematuria |
7.4% |
| Interstitial Lung Disease |
7.4% |
| Cryptogenic Organising Pneumonia |
5.6% |
| Delirium |
5.6% |
| Rash |
5.6% |
| Stomatitis |
5.6% |
| Toxic Epidermal Necrolysis |
5.6% |
| Vomiting |
5.6% |
| Drug Eruption |
3.7% |
| Duodenal Stenosis |
3.7% |
| Malaise |
3.7% |
| Myocardial Ischaemia |
3.7% |
| Pyrexia |
3.7% |
| Renal Failure Chronic |
3.7% |
| Stress Cardiomyopathy |
3.7% |
| Visual Acuity Reduced |
3.7% |
| Blood Creatine Phosphokinase Increased |
1.9% |
| Blood Glucose Decreased |
1.9% |
|
| Concomitant |
| Hiv Infection |
22.5% |
| Acquired Immunodeficiency Syndrome |
11.5% |
| Bronchitis |
10.1% |
| Product Used For Unknown Indication |
7.5% |
| Mycobacterium Avium Complex Infection |
6.1% |
| Prophylaxis |
5.5% |
| Drug Use For Unknown Indication |
4.9% |
| Pneumonia |
4.7% |
| Rheumatoid Arthritis |
4.3% |
| Pharyngitis |
3.6% |
| Antifungal Prophylaxis |
2.9% |
| Hypertension |
2.5% |
| Opportunistic Infection Prophylaxis |
2.1% |
| Depression |
2.0% |
| Cytomegalovirus Infection |
1.7% |
| Cytomegalovirus Oesophagitis |
1.7% |
| Infection Prophylaxis |
1.7% |
| Insomnia |
1.7% |
| Pneumocystis Jiroveci Pneumonia |
1.5% |
| Pyrexia |
1.5% |
|
| Rash |
10.4% |
| White Blood Cell Count Decreased |
10.4% |
| Pneumonia |
7.3% |
| Renal Impairment |
7.3% |
| Malaise |
6.3% |
| Visual Field Defect |
6.3% |
| Vomiting |
6.3% |
| Interstitial Lung Disease |
5.2% |
| Weight Decreased |
5.2% |
| Brain Herniation |
4.2% |
| Drug Exposure During Pregnancy |
4.2% |
| Hepatic Function Abnormal |
4.2% |
| Platelet Count Decreased |
4.2% |
| Hepatic Enzyme Increased |
3.1% |
| Liver Disorder |
3.1% |
| Lymphocyte Stimulation Test Positive |
3.1% |
| Pyrexia |
3.1% |
| Acute Respiratory Distress Syndrome |
2.1% |
| Adrenal Insufficiency |
2.1% |
| Bone Marrow Failure |
2.1% |
|
